In a major move to secure the nation’s medical supply chain, Franklin Lakes-based Becton, Dickinson and Company (BD) announced a landmark partnership with the U.S. Government aimed at significantly expanding domestic manufacturing and strengthening American healthcare resilience.
The agreement anchors a multi-year $19 billion investment by BD in capital, operational, and supply chain initiatives across the United States. Of that total, $3 billion will be directly targeted toward expanding U.S. manufacturing infrastructure across strategic production hubs—including facilities in Nebraska, Connecticut, Puerto Rico, Utah, Texas, Georgia, and South Carolina.
As the nation’s largest manufacturer of essential medical consumables—items used in approximately 90% of U.S. hospital visits—BD’s new initiative focuses heavily on scaling up domestic volume. The partnership is projected to:
- Expand end-to-end U.S. production by approximately 5 billion essential medical consumables annually.
- Raise BD’s share of domestically supplied essential medical consumables to roughly 80%.
- Ensure that 100% of BD needles used in the United States are manufactured domestically utilizing American-made steel.
“This agreement reflects a shared commitment between the U.S. Government and BD to strengthening America’s healthcare infrastructure,” Tom Polen, chairman, CEO, and president of BD said. “The administration recognizes the importance of investing in a stronger, more secure healthcare supply chain, and BD is uniquely positioned to help bring that vision to life through our scale, innovation expertise, and longstanding U.S. manufacturing footprint.”
In exchange for meeting agreed-upon manufacturing milestones, the partnership provides relief from future Section 232 tariffs on covered BD products and raw material inputs. Because final tariff rates, exact product scopes, and effective timelines are still under development, BD has indicated it will quantify the specific financial impacts once those federal actions are finalized. Company leadership notes that the arrangement offers critical long-term certainty for domestic manufacturing and supply chain planning.
With a manufacturing footprint spanning nearly 130 years, BD has frequently collaborated with federal authorities during national health crises—from developing early disposable syringes to aid the fight against polio, to delivering more than two billion devices during recent public health emergencies.
Company executives emphasize that this new initiative builds upon that legacy, establishing one of the world’s most robust manufacturing bases for essential medical supplies and safeguarding healthcare access for future generations.
